Skip to content

Trans-abdominal Fetal Pulse Oximetry: Signal Integrity

Trans-abdominal Fetal Pulse Oximetry: Signal Integrity

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04081623
Enrollment
9
Registered
2019-09-09
Start date
2019-04-16
Completion date
2021-06-08
Last updated
2021-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Distress

Brief summary

This project is set up to advance and integrate the established mathematical principles of oxygen saturation to model with increasing accuracy the body in a body problem of fetus in mother; similar to existing pulse oximeters,

Detailed description

The investigational device is a non-invasive fetal pulse oximeter that measures fetal arterial pulse signal using safe, noninvasive, transabdominal near-infrared spectroscopy. The optical sensor will obtain fetal pulse oximetry signals. Women will also undergo sonographic evaluation to assess distance from maternal skin to fetal tissue and to confirm fetal presentation and position. There is no change to standard of care procedures for fetal heart rate monitoring. The fetal heart rate that will be monitored with the investigational device will be used for research purposes only. Results will not be used to guide or alter patient management.

Interventions

DEVICERaydiant Oximetry Sensing System

The investigational device is used to record fetal pulse signals.

Sponsors

Raydiant Oximetry, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Pregnant women with singleton pregnancies, vertex presentation 2. Age ≥ 18 years 3. Healthy women ≥ 28 weeks gestation undergoing either Non-Stress test (NST) or Biophysical profile (BPP) OR 4. Healthy women ≥ 37 weeks in labor 5. Vertex presentation

Exclusion criteria

1. Age \<18 years 2. Multiple gestation ( twins, triplets) 3. Presentation other than vertex 4. \< 28 weeks of gestation

Design outcomes

Primary

MeasureTime frameDescription
Fetal signal integrityDuring NST, BPP, or active laborIntegrity of the fetal signal relative to background maternal signal and biologic/electronic noise, and related to fetal position, presentation and the depth of the fetus from maternal skin.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026